The number of Americans with HF is increasing. Despite the many agents approved to manage HF, the prognosis has only improved somewhat, with a 5-year mortality rate after initial hospitalization of 42.3%. Guidelines are frequently updated, with the most recent ACC consensus on optimizing treatment published in 2021. Some agents to treat HFrEF are relatively new and several agents are in late-stage development. For patients with HFpEF there are currently no approved therapies although there are agents in phase 3 clinical trials.
Heart Failure: Evolving Treatment Choices and New Guidance will address the rapidly shifting HF management paradigm, providing information about the most recent evidence-based recommendations for managing HFrEF, newer approved agents, and those agents for which approval is anticipated soon, as well as agents in late-stage investigation for the management of HFpEF.
Jointly provided by the Potomac Center for Medical Education and Rockpointe
This program is supported by an educational grant from Merck & Co, Inc.
Clicking Start Activity indicates that you have reviewed the CME/CE information for this activity
Managing Heart Disease in Type 2 Diabetes: Incorporating Diabetes Drugs into the Management of Cardiometabolic Disease (Regionals)
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.